TIDieR checklist evaluation of clinical trial intervention reporting for recent FDA-approved anticancer medications.
Cole WayantRichard BindernagelMatt VassarPublished in: BMJ evidence-based medicine (2019)
In this analysis of clinical trials of recent, FDA-approved anticancer interventions, we found good adherence to the TIDieR checklist. These studies were homogeneous in their structure and included information; some TIDieR items were always or never/rarely reported. Clinical trial effect sizes may not translate to real-world practice for a number of reasons. Thus, to aid the translation of trial effect sizes to real-world practice, we recommend authors adhere to the TIDieR checklist and describe the infrastructure of trial centres and describe who provided the intervention, along with their expertise.